Important information about COVID-19
COVID-19 and aHUS/Eculizumab
Patients with aHUS receiving eculizumab should continue to receive their eculizumab during the current COVID-19 pandemic
As of 22/03/2020 the UK government has updated its advice for extremely vulnerable patients (available here).
- For aHUS patients on Eculizumab with a renal transplant the government advice is clear – implement shielding i.e. staying at home and avoiding any face-to-face contact for a period of at least 12 weeks.
- For aHUS patients on Eculizumab (not transplanted), shielding may be appropriate depending on your general health, age (>70yrs) and stage of kidney function (CKD stages 3, 4 or 5) which is best assessed by your primary nephrologist and we are happy to assist them in this decision (for further information click here.)
As a minimum all aHUS patients on Eculizumab should be particularly stringent in following social distancing measures (please click here for the government link).
Patients on eculizumab remain at risk of meningococcal sepsis and should continue on their prophylactic antibiotics and seek medical advice (presenting with your meningococcal risk card) if they believe they have symptoms (summarised here) suggestive of meningococcal sepsis
Patients in the Stopping Eculizumab Treatment Safely (SETSaHUS) should continue with standard monitoring as described in the SETSaHUS information pack
If individuals have previously been told by a medical professional that they are at risk of developing aHUS, standard advice about seeking medical advice with their “aHUS at-risk” card applies if they are unwell and think that they have symptoms of aHUS
There is currently no evidence suggesting eculizumab worsens COVID19 however this is a rapidly evolving field. Many patients on Eculizumab will have co-existent chronic kidney disease, renal transplants and other health conditions necessitating the above measures.
Atypical Haemolytic Uraemic Syndrome (aHUS) & Eculizumab Specialists
NRCTC specialises in Atypical Haemolytic Uraemic Syndrome (aHUS), Eculizumab, C3 Glomerulopathy (C3G) and MPGN.
Members of our team have been instrumental in research into pathogenic mechanisms of aHUS that has revealed the important role of complement.
Approximately 50% of patients with aHUS have an underlying complement abnormality. Eculizumab is a complement inhibitor that was recommended by NICE in the treatment of aHUS in England.
Eculizumab is currently funded by NHS England through the national aHUS service based within the National Renal Complement Therapeutics Service at the Newcastle upon Tyne Hospitals NHS Foundation Trust.